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Abstract
Background—Mifepristone is a glucocorticoid receptor inhibitor shown in vitro to have anti-
HIV activity and anti-simian immunodeficiency virus activity in a macaque model. A phase I/II
trial was performed to assess the drug’s safety and anti-HIV activity.
Methods—A 28-day double-blind, placebo-controlled trial of mifepristone at doses of 75 mg,
150 mg, and 225 mg given daily was conducted in HIV+ persons with CD4+ lymphocyte counts
≥350 cells per cubic millimeter who had no recent antiretroviral therapy.
Results—Fifty-six male and 1 female subjects with a median entry CD4+ lymphocyte count of
555 cells per cubic millimeter and plasma HIV-1 RNA of 15,623 copies per milliliter were
accrued. Forty-five subjects (78.9%) were available for endpoint analysis. In each arm, changes
from baseline to day 28 in plasma HIV-1 RNA and CD4+ lymphocyte count were not significantly
different from zero (no change). There was no relationship between mifepristone trough
concentrations and plasma HIV-1 RNA. Day 28 morning plasma cortisol levels were significantly
higher in the 150 mg and 225 mg arms compared with placebo, confirming biologic activity, and
returned to baseline by day 56. Serum lipids did not change during the trial. Fasting blood sugar
was 2.5 mg/dL higher on day 28 in the mifepristone arms, but the Homeostasis Model Assessment
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of Insulin Resistance (HOMA-IR) did not change. Three subjects (7.3%) receiving mifepristone
developed a grade 2 rash.
Conclusions—Mifepristone at doses of 75–225 mg daily was safe and well-tolerated, but did
not show significant anti-HIV activity.
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An essential step in HIV replication is integration of its genome into the host cell
chromosomes within the nucleus.1 HIV transports its genetic material as a large,
nucleoprotein preintegration complex (PIC) into the nucleus through the intact nuclear
envelope.
Viral protein R (Vpr) was originally classified as an accessory protein because it was
thought to be dispensable for virus replication in T-lymphocyte lines.2 More recently Vpr
and its receptor (hVIP/mov34) have been reported to form an activated receptor complex
with the glucocorticoid receptor II (GR-II).3–5 Vpr induces nuclear translocation of the PIC.
Because inhibiting PIC nuclear import should block HIV replication in nondividing cells,
this critical step of HIV replication is of interest as a drug target. Vpr shares many
characteristics with glucocorticoids, including the inhibition of its activities by the potent
antiglucocorticoid compound mifepristone.3,4,6 Mifepristone inhibits the Vpr-mediated
nuclear translocation of the Vpr receptor and blocks Vpr-induced apoptosis, cytokine
production, and T-cell proliferation.4 In addition, by blocking the nuclear translocation of
PIC, mifepristone has been shown to effectively inhibit replication of laboratory and clinical
HIV-1 isolates, including drug-resistant strains, divergent clades, and those that use CCR5
and CXCR4 coreceptors. Furthermore, studies of intravenous mifepristone in an simian
immunodeficiency virus (SIV)–infected macaque model have shown antiretroviral activity.7
In vitro, mifepristone inhibits HIV replication at concentrations ranging from 40 nM to 1000
nM (17–430 ng/mL), with an IC50 of 8 nM.3 These concentrations are readily achievable in
vivo. Clinical studies using daily doses of 1–200 mg of mifepristone achieved steady-state
drug concentrations of 85–5400 nM.8–11 Chronic administration of up to 200 mg/day of
mifepristone for the experimental treatment of a variety of malignant and nonmalignant
conditions has been well tolerated in non–HIV-infected subjects for up to 1 year.12–15 These
data supported investigations of the in vivo antiviral effects of mifepristone on HIV
replication and CD4+ T-cell counts in humans. The primary goal of this trial was to
determine whether mifepristone in doses up to 225 mg/day showed antiretroviral activity in
vivo in patients not receiving other antiretroviral therapy (ART).
METHODS
To evaluate the antiviral efficacy and safety of mifepristone, a double-blind, randomized,
placebo-controlled phase I/II study was undertaken of 3 dose levels (75, 150, and 225 mg/
day) of orally administered mifepristone for 28 days. This trial was sponsored by the AIDS
Clinical Trials Group and given the number A5200.
Documented HIV-1–infected subjects ≥18 years of age with CD4+ cell count ≥350 cells per
cubic millimeter and plasma HIV-1 RNA of ≥2000 copies per milliliter (within 90 days
before study entry) were recruited for enrollment. Subjects had not received antiretroviral
treatment within the 16 weeks before study entry nor intended to initiate ART within 60
days after entry. This population was selected because ART was not routinely recommended
for them according to the then current United States Public Health Service (USPHS)
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guidelines.16 The subjects also needed to have stable hepatic, renal, endocrine (TSH
between 0.5–6.0 mIU/L and a stimulated plasma cortisol ≥20 µg/dL) and hematological
indices.17 Subjects were excluded if they were pregnant or breast feeding; had any chronic
medical conditions such as adrenal insufficiency, active hepatitis, porphyria, cirrhosis,
hemorrhagic disorders; prior pituitary tumor, surgery, or failure; diabetes requiring medical
treatment; dysfunctional uterine bleeding within the past 12 months; currently had an
intrauterine device; or weighed less than 40 kg. Subjects who were using potent inhibitors or
inducers of cytochrome P450 3A4, anticoagulants, hormonal contraception, and any use in
the past 90 days of corticosteroids, other hormones, immunomodulators, HIV vaccines, or
investigational therapy were also excluded.
Subjects were enrolled at 8 ACTG sites. At entry, they were randomized, in permuted blocks
without institutional balancing, with equal probability to 1 of 4 arms. Mifepristone was
administered at the following doses in the 3 active arms: arm 1—75 mg (1 tablet); arm 2—
150 mg, (2 tablets); and arm 3–225 mg (3 tablets). Subjects administered placebo were
randomized to receive 1, 2 or 3 placebo tablets. Thus, the subjects and investigators were
blinded as to whether subjects received active drug or placebo but not to dose group.
Subjects self-administered the assigned number of study tablets once daily in the morning
with a light meal for 28 days. Mifepristone was supplied as 75 mg tablets from Viral
Genomics Pharmaceuticals with a matching placebo made with the excipients only.
At each study visit, subjects were asked about drug adherence, screened for any grade ≥1
adverse events (AEs), and had vital signs, including an assessment of orthostasis. Targeted
physical examination driven by any previously identified signs or symptoms were
performed. Safety blood studies were obtained weekly while on study drug (28 days) and 4
weeks afterwards. These included routine hematology, chemistries, liver and pancreas
function tests, and CD4+/CD8+ lymphocyte counts. Lipids, insulin, and free fatty acids,
morning cortisol, and a urinalysis were obtained on the first and last day of mifepristone.
Plasma HIV-1 RNA determinations were performed on days 0, 3, 7, 14, 21, 28, and 56.
Predose mifepristone levels were obtained on days 14 and 28.
Any subject who experienced a grade ≥3 AE, or a grade ≥2 rash, as defined in the Division
of AIDS Table for Grading Adult Adverse Experiences,17 considered to be possibly or
probably related to study drug was permanently discontinued from further treatment. All
other grade ≥3 toxicities were reviewed by the safety monitoring committee and team. The
study included a mechanism for early stopping in the case of prohibitively high toxicity/
intolerance rates defined as ≥3 adverse event or ≥2 rash. Subjects who missed 3 or more
doses of study medication during the first 14 days on study or who failed to provide a day 28
plasma HIV-1 RNA were excluded from primary analyses and were therefore replaced in
accrual but were asked to attend remaining study visits.
Statistical Considerations
The primary endpoint was the within-subject change in log10 plasma HIV-1 RNA from
baseline to days 14 and 28. For each arm, these changes were compared with the fixed
hypothesized value of zero (no change), using the one-sided, one-sample t test with
significance level 0.05. The study was powered to detect clinically meaningful short-term
decreases in HIV-1 RNA within each active dose level, not to detect differences in
antiretroviral activity between the active doses. Assuming standard deviations of changes to
be about 0.6 log10, 12 evaluable subjects in each arm gave 85% power to detect mean
changes in log10 HIV-1 RNA, in any one arm, at days 14 and 28 of 0.5 log10 copies per
milliliter or greater. The placebo group provided comparison data for the safety and
tolerability objective.
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Fifty-seven subjects were enrolled and randomized over a 4 month period. Twelve subjects
were not evaluable for the primary endpoint analysis. Four had protocol-defined toxicities, 3
with rash, and 1 neutropenia. Six received prohibited drugs (for 3, concurrent administration
of prohibited medications was discovered after the trial was complete), 1 was non-adherent
to the regimen, and for 1 subject, the plasma HIV-1 RNA assay could not be conducted
(poor sample condition). Thus 45 subjects were included in the primary analysis.
Demographic and clinical characteristics by arm are shown in Table 1. Median entry CD4+
lymphocyte count was 555 cells per cubic millimeter and plasma HIV-1 RNA was 4.19
log10 copies per milliliter. Pill counts to assess study drug compliance showed no missed
doses at 89% of study visits.
Figure 1 shows the anti-HIV response to mifepristone. For all arms combined, subject-
specific changes in plasma HIV-1 RNA were small, ranging from −0.65 to +0.67 log10
copies per milliliter, and the null hypothesis of no change could not be rejected. Pooling
active arms, changes were also not different from zero (P = 0.855). Day 28 antiviral efficacy
is also represented in Table 1; for all arms, the 95% confidence intervals include the value
zero. In a secondary analysis using all available day 28 viral loads, this finding holds for the
active arms. Figure 1 and Table 1 also show the CD4+ lymphocyte response over the time to
the study drugs. Again, no statistically significant increases in CD4+ cell count were seen in
the active arms.
Mifepristone was generally well tolerated. There were similar rates of protocol-defined
toxicities in the placebo (6.3%) and the mifepristone arms (7.3%). Rash has been reported in
prior studies of mifepristone. In this study, 3 subjects receiving mifepristone developed a
grade 2 rash by week 2, none of which were dose related. Because mifepristone blocks
glucocorticoid receptors, there was concern for the development of symptoms of
hypoadrenalism, but no grade 3 symptoms consistent with adrenal insufficiency were noted.
The incidence of all grade 3 or higher toxicities is shown in Table 1. There was overlap
around the 95% confidence interval for the rates of all AEs, and all grade 3 toxicities were
related to laboratory abnormalities.
Plasma and serum mifepristone trough values were obtained with good correlation observed
between the day 14 and 28 values (Pearson correlation coefficient r = 0.96, P < 0.001) and a
strong linear association (r > 0.99, P < 0.001) between the serum and plasma concentrations
(data not shown). Plasma concentrations of mifepristone, shown in Table 1, increased with
dose but not linearly. The difference between the 75 mg and 150 mg does was much larger
than between the 150 mg and 225 mg dose. The mean concentrations of the 75 mg, 150 mg,
and 225 mg doses of mifepristone were 271.9, 788.2, and 792.8 ng/mL, respectively. There
was considerable overlap between the 150 and 225 mg arms with no significant difference in
levels. This is consistent with prior studies of mifepristone that doses above 150 mg did not
yield increases in serum drug levels. Higher mifepristone concentrations were not associated
with greater decreases in plasma HIV-1 RNA levels at day 28.
To assess whether mifepristone was biologically active, morning cortisol levels were
measured on day 28. As shown in Table 1, cortisol levels increased with mifepristone dose
and were significantly different from the zero on the 3 active arms (paired t test P values =
0.023, 0.017, 0.0020, respectively), but not the placebo arm (P = 0.165). By day 56, cortisol
levels had returned to baseline, and changes were not significantly different from zero on
any arm.
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Plasma lipids and measures of insulin sensitivity were performed on day 0 and 28. Changes
in cholesterol, triglycerides, fatty acids, fasting blood sugar, and insulin did not seem to
increase or decrease with dose level and were not different between active and placebo arms.
CONCLUSIONS
In this randomized partially blinded placebo-controlled phase I/II trial of mifepristone at
doses up to 225 mg/dL, there was no evidence of antiretroviral activity over a 28-day period.
This was true despite the fact that there was a measured increase in serum cortisol levels at
the 150 and 225 mg daily doses that confirmed the in vivo biologic activity of the
mifepristone. The drug at these doses was safe and well tolerated.
The discordance of the results of the in vitro systems and macaque model and those in our
trial may have been from inadequate drug action or levels at the target site. In the macaque,
the mifepristone was given intravenously and thus avoided gut and hepatic metabolism that
could have occurred with the oral dosing in the trial. The IV administration in macaques (3.2
mg/kg) may have obtained higher free drug levels than achieved in subjects receiving 225
mg of mifepristone orally, although preclinical studies of orally dosed cynomolgus monkeys
suggested the serum drug levels were 6-fold higher in man. Another possibility for lack of
correlation in efficacy may have resulted from differential binding of the mifepristone to
serum proteins or its cellular receptors in the SIV model compared with those in an HIV-
infected human. A difference in the affinity or concentration of VIP/mov34 receptor on T-
lymphocytes between the SIV model and man could also explain the lack of activity.
Alternatively, incomplete mifepristone interference of the HIV PIC and glucocorticoid
receptor II interaction in vivo might have prevented more complete viral inhibition. No
studies were conducted to assess the affinity of these cellular receptors in primates or in the
patients tested. Although this trial did not demonstrate antiviral activity as expected, a trial
evaluating higher doses of mifepristone in a similar HIV-1–infected population is underway
with the hope of identifying another HIV therapeutic agent.
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Arm-specific change in plasma log10 HIV-1 RNA (copies/mL, upper panel) and in CD4+
lymphocyte count (cell/mm3, lower panel) by scheduled study day. Dotted horizontal lines
marks zero (no change).
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